Updates
** Shares of drugmaker Amgen AMGN.O gain 5.54% to $305.04, reversing premarket losses
** Co on Tuesday reported Q4 profit of $5.31 per share, beating estimates of $5.08 - LSEG data
** Said late-stage studies of key obesity drug candidate MariTide will start before mid-year
** However, U.S. FDA has placed clinical hold on early-stage trial of experimental weight-loss drug AMG 513
** AMGN does not believe issue leading to the hold is drug-related
** Obesity will continue to be key theme for Amgen shares as we enter 2025, brokerage BMO Capital Markets says
** Up to last close, stock down ~10% in last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。